iGan Partners Secures $10 Million for Exact Imaging's Prostate Cancer Detection Advancements

iGan Partners Secures Funding for Exact Imaging's Groundbreaking Technology

In a significant move to fight against prostate cancer, iGan Partners has successfully closed a $10 million financing round for Exact Imaging, a pioneer in high-resolution micro-ultrasound technology aimed at improving urologic imaging. This funding is aimed at accelerating the global reach and adoption of their flagship product, the ExactVu™ prostate biopsy system.

Financial Milestone for Exact Imaging

This latest round of financing comes after a year full of advancements for Exact Imaging, especially in 2025, where the company made commendable strides in clinical validation and commercialization of its products. Notably, the OPTIMUM study, which was published in the prestigious JAMA journal — recognized as one of the leading medical journals worldwide — highlighted the efficacy of ExactVu™ in detecting prostate cancer in biopsy-naive men, proving to be non-inferior to MRI-fusion biopsy techniques.

The achievement was so notable, it was even featured during the “Game Changer” session at the European Association of Urology Congress held in Madrid. These advancements have helped Exact Imaging in establishing a broader commercial footprint, including the launch of a dedicated North American sales team and strategic partnerships with distributors in various international markets, such as Japan, South Korea, and multiple countries in Europe and Latin America.

According to Randy AuCoin, the CEO of Exact Imaging, this investment represents a critical milestone as they push to expand their commercial reach and bring ExactVu™ to more urologists and patients worldwide.

The Role of iGan Partners

iGan Partners, Exact Imaging's largest shareholder, has played a pivotal role since the company’s foundation. Founded by Sam Ifergan, iGan Partners has been instrumental in supporting Exact Imaging across various stages, including company formation, intellectual property licensing, and various financing rounds.

"The partnership between Randy and me goes back many years, and it has been an honor to support his vision in creating a revolutionary company within the healthcare space," expressed Ifergan.

As Exact Imaging significantly grows, with expectations to double its sales figures in 2026, investing in scalable technologies like the ExactVu™ system shows how serious iGan Partners is about impacting patient care and improving outcomes.

The Future of Prostate Cancer Detection

Exact Imaging's commitment to advancing urological imaging and prostate cancer detection could potentially change lives. With a portfolio of over 100 patented technologies, the ExactVu™ system has already caught the attention of over 300 urologists around the world, emphasizing its position in a market where each urologist should have access to high-resolution imaging systems.

As this investment leads to expanded clinical usage and greater outreach, the fight against prostate cancer could see revolutionary changes, improving not just detection rates but patient outcomes on a larger scale.

The future for Exact Imaging looks promising, with ambitious plans to continue innovating and catering to the needs of urologic care globally, thanks in large part to the support it continues to receive from iGan Partners.